Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
HeLIX Exploration says new study shows Rudyard project could generate clean hydrogen naturally
11:21am, Thursday, 16'th Oct 2025
HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) shares were up on Thursday, after it announced breakthrough results confirming both mantle helium and...
Allergy Therapeutics update delivers welcome dose of good news
07:15am, Thursday, 16'th Oct 2025
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has given investors something to cheer about. The AIM-listed biotech climbed 3.3% to 8.25p after reporting...
Thor Explorations stays on track as Q3 gold output hits 22,600 oz
03:36am, Wednesday, 15'th Oct 2025
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) reported steady third-quarter production at its Segilola gold mine in Nigeria and reaffirmed its...
Empire Metals is now "one of the world’s largest titanium deposits"
03:30am, Tuesday, 14'th Oct 2025
Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has announced a maiden Mineral Resource Estimate confirming one of the world’s largest titanium deposits at its...
KEFI shares surge 19% as Tulu Kapi financing deal nears completion
05:13am, Monday, 13'th Oct 2025
Shares in KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) jumped 19% on Monday after the company said it expects to finalise a $240 million debt financing...
Power Metal Resources shares rise as GSAe advances talks
05:07am, Monday, 13'th Oct 2025
Power Metal Resources PLC (AIM:POW, OTCQB:POWMD) shares moved higher in Monday's early deals, after the firm said its 75%-owned subsidiary, GSA...
Helium One eyes first helium production, exits funding arrangement early
03:57am, Monday, 13'th Oct 2025
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) said development of the Galactica-Pegasus helium project in Colorado, is progressing on schedule, with first...
KEFI set to sign $240m financing for Tulu Kapi gold mine
03:28am, Monday, 13'th Oct 2025
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) said it expects to sign a $240 million debt financing deal for its Tulu Kapi gold project in Ethiopia this...
All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy
01:01pm, Friday, 10'th Oct 2025
AIM ImmunoTech (AIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oxford BioDynamics shares soar 33% after unveiling breakthrough blood test for Chronic Fatigue Syndrome
04:45am, Wednesday, 08'th Oct 2025
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) shares surged 33% on Wednesday after the company announced it had developed a highly accurate blood test to diagnose Chronic Fatigue Syndrome, a condition t
Oxford BioDynamics unveils blood test for Chronic Fatigue Syndrome with 96% accuracy
02:59am, Wednesday, 08'th Oct 2025
Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) has developed what it calls a “first-in-class” blood test to diagnose Chronic Fatigue Syndrome, a breakthrough that could help end years of uncertainty
Pantheon Resources completes Dubhe-1 stimulation in Alaska
02:43am, Wednesday, 08'th Oct 2025
Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has successfully completed hydraulic fracture stimulation operations at the Dubhe-1 well on Alaska's North Slope. The 25-stage plug-and-perforate program
Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth
Shield raises £1.5m to support growth of flagship iron deficiency drug
03:24am, Monday, 15'th Sep 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has raised £1.5 million from institutional investors to support the growth of its iron deficiency treatment, ACCRUFeR. The AIM-listed drugmaker said it
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
11:00am, Thursday, 04'th Sep 2025
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-
